Repository logoGCRIS

Tıp Fakültesi Koleksiyonu

Permanent URI for this collectionhttps://hdl.handle.net/11499/46004

Browse

Filters

Settings

COAR Resource Type: search.filters.itemCoarResourceType.text::journal::journal article

Search Results

Now showing 1 - 10 of 3486
  • Article
    Aesthetic Interventions in Patients with Allergic Skin Diseases: Risk Assessment and Evidence-Based Preventive Risk Management
    (Elsevier Inc., 2026-03) Yiğit, İçim Kömürcügil; Türsen, Ümit; Türsen, Belma; Solak, Berna; Bakay, Özge Sevil Karstarlı; Kroumpouzos, George
  • Article
    Tideglusib Accelerates Bone-Tendon Interface Healing and Improves Mechanical Strength in a Rabbit Rotator Cuff Tear Model: An Experimental Study
    (BMC, 2026-02-14) Ocaklar, Zeynel Can; Unal, Murat Serkant; Yorukoglu, A. Cagdas
    Background The present study aimed to investigate the effects of the glycogen synthase kinase-3 (GSK-3) inhibitor tideglusib on bone-tendon interface healing in a rabbit model of rotator cuff injury, based on biomechanical and histological assessments. Methods Fourteen New Zealand rabbits underwent supraspinatus tendon detachment to establish a chronic rotator cuff tear model. After six weeks, surgical repair was performed. In the right shoulders, tideglusib was administered at the bone-tendon junction prior to performing the primary repair (drug group), whereas the left shoulders underwent primary repair without biological augmentation (control group). Seven animals were included in the group subjected to biomechanical tension testing, and six for histological evaluation. Results Biomechanical evaluation demonstrated that the tideglusib group showed significantly higher load-to-failure values compared with the control group the control group (p < 0.05), whereas elongation at failure showed no statistically significant difference. Histological scoring demonstrated significantly improved cellular organization and tissue healing in the tideglusib group (p < 0.05). Conclusion Local application of tideglusib positively enhances tendon-bone healing both biomechanically and histologically. Further studies are warranted to explore its potential clinical applications.
  • Article
    Synthesis and Comparative Biological Analysis of Mixed NHC/L Platinum (II) Complexes: Anticancer and Antimicrobial Properties
    (Elsevier B.V., 2026-08) Aslan, Sümeyye; Bugday, Nesrin; Boulebd, Houssem; Yüce, Hande; Türkmen, Neşe Başak; Özek, Dilan Aşkın; Günal, Selami ; Berberoğlu, Yasemin; Eke, Benay Can; Yaşar, Sedat; Ünüvar, Songül
    Platinum-N-heterocyclic carbene (Pt-NHC) complexes have garnered significant interest as potential anticancer agents, with their efficacy influenced by their structural characteristics and ligand environments. In this study, eight of Pt-NHC complexes were synthesized via a one-pot synthesis method from related NHC precursors, which have different electronic and steric properties, and fully characterized by (1H and 13C) NMR, HRMS, FT-IR spectroscopy, and elemental analysis. Their anticancer and antimicrobial properties were evaluated by investigating cytotoxicity, inhibition of cancer cell migration, antimicrobial and antifungal activities, and apoptotic effects. The Pt-NHC complexes demonstrated notable antiproliferative and anti-migratory effects against SHSY5Y (human neuroblastoma), A549 (human lung cancer), MDA-MB-231 (human breast cancer), and HeLa (human cervical cancer) cell lines, as well as significant antimicrobial activity against S. aureus, C. albicans, and MRSA strains. Molecular docking analyses were performed to explore interactions between the complexes and cancer cell targets. Variation in the Bax/Bcl-2 ratio highlighted differences in apoptotic regulation across cancer cell lines. Notably, the Pt-NHC complexes exhibited greater efficacy than cisplatin, underscoring their promise as candidates for drug development, although further investigation into the complex roles of Bax and Bcl-2 in apoptosis is needed for a comprehensive evaluation of these new therapeutic agents.
  • Article
    Resectable Stage Early-Onset Biliary Tract Cancer: Survival and Prognostic Scoring (EOB-RS and EOB-OS) in Turkish Patients (TOG/GI-SAFRADJU-2502-EO)
    (Lippincott Williams & Wilkins, 2026-03) Akkus, Erman; Kayaalp, Mehmet; Ergözoğlu, Müzeyyen Aslı; Koç Kuş, Ilgın; Bayram, Doğan; Kılıçtaş, Bilgeşah; Ayvaz Güneyin, Emel ; Kalem, Ali; Temizyürek, Haydar; Çatlı, Mehmet Mutlu; Akarca, Mehmet Sinan; Mıldanoğlu, Maral Martin; Turhan, Görkem; Kara, Mahmut; Arak, Hacı; Arslan Tan, Feyza; Paçacı, Burak; Yeşilyurt, Berkay; Akdoğan, Orhun; Ala Enli, Şeymanur; Yasar, Hatime Arzu
    PURPOSE Early-onset gastrointestinal cancers are concerning entities globally, yet early-onset biliary tract cancers (EOBTCs) are understudied. Early-stage disease is crucial for young patients' survival. METHODS TOG/GI-SAFRADJU (ClinicalTrials.gov identifier: NCT06975917) is a multicenter, hospital-based, registry initiative of the Turkish Oncology Group, including patients with resected BTCs. Early-onset was defined as a diagnosis at age <50 years. Characteristics and survival of EOBTC and non-EOBTC were compared. Among patients with EOBTC, prognostic factors for recurrence-free survival (RFS) and overall survival (OS) were analyzed. Risk scores were assigned on the basis of hazard ratios. RESULTS Six hundred seventeen patients from 44 centers were included. 12.6% (n = 78) were EOBTC. R1 resection rate was significantly higher among EOBTC (37.1% v 25.7%, P = .038). Adjuvant treatments did not differ between EOBTC and non-EOBTC. Among patients who received adjuvant chemotherapy, RFS (13.9 months [95% CI, 11.4 to 22.1] v 15.9 months [95% CI, 13.6 to 18.9], P = .947) and OS (35.6 months [95% CI, 28.0 to 81.4] v 31.3 months [95% CI, 27.8 to 44.3], P = .670) were similar between EOBTC and non-EOBTC groups. Among patients with EOBTC, R1-resection and high CA19-9 levels were associated with shorter RFS, and gallbladder localization and high CA19-9 were associated with shorter OS in adjusted analyses. Using these factors, risk scores early-stage EOBTC RFS score (EOB-RS) for RFS and early-stage EOBTC OS score (EOB-OS) for OS were formed, each including three ranks. Both scores significantly ordered the prognosis of patients with EOBTC (EOB-RS, [0 points]: 22.7 months, [1 or 2]: 10.3 months, [3]: 5.7 months, P < .001, EOB-OS: [0]: 110.9 months, [1 or 2]: 29.6 months, [3]: 10.1 months, P < .001). CONCLUSION Resected EOBTC patients showed survival comparable to older counterparts receiving surgery/adjuvant therapy. This study suggests a potential risk scoring system for early-stage EOBTC, pending validation.
  • Article
    Prognostic Implications of Serum C3 Levels in Primary Membranous Nephropathy: A Retrospective Cohort Analysis
    (Asoc Regional Dialisis Trasplantes Renales, 2026) Onan, Engin; Artan, Ayse Serra; Oruc, Aysegul; Doksan, Muge; Eren, Necmi; Karadag, Serhat; Şahin, Gülizar ; Turgutalp, Kenan; Seyahi, Nurhan; Kutlay, Sim; Cevher, Şimal Köksal; Dursun, Belda; Pınar, Musa; Ayli, Mehmet Deniz; Baştürk, Taner; Ustundag, Garip Şahin Sedat; Yılmaz, Zülfükar; Yadigar, Serap; Güngör, Özkan; Tatar, Erhan; Öztürk, Savaş
    Background: The complement system plays a crucial role in the pathogenesis of membranous nephropathy (MN). Serum complement 3 (C3) levels may be a prognostic marker. This study investigates the prognostic significance of serum C3 levels in patients with primary MN. Methods: This study aims to evaluate the prognostic value of serum C3 levels in primary MN by analyzing their associations with demographic, clinical, and histopathological features, as well as treatment outcomes. We used data from the Turkish Society of Nephrology Glomerular Diseases (TSN-GOLD) Working Group, a nationwide registry. Results: A total of 1,259 biopsy-proven primary MN patients were included. Serum C3 levels were low in 45 (3.6%) patients. Patients with low serum C3 levels demonstrated higher baseline serum creatinine (1.3 +/- 1.1mg/dL vs. 0.9 +/- 0.8mg/ dL, p=0.006) and proteinuria (9714 +/- 6329 mg/24h vs. 7052 +/- 4463mg/24h, p=0.002), and lower albumin levels (2.3 +/- 0.8g/dL vs. 2.7 +/- 0.8g/ dL, p=0.007) compared to those with normal serum C3. At one-year follow-up, both groups showed significant decreases in proteinuria and increases in albumin levels. In repeated-measures analyses, creatinine and proteinuria showed significant differences over time between the C3 groups; albumin did not (p: 0.029, 0.013, and 0.705, respectively). The remission rates were not different between C3 groups, 10 cases (62.5%) in the Low group, and 432 cases (76.1%) in the Normal group, p: 0.237. Relapse rates were notably higher in patients with low serum C3 levels compared to those with normal serum C3 (62.5% vs. 38.0%, p=0.049). Multivariate analysis showed that age (HR: 1.017, 95% CI: 1.002-1.032, p=0.025) and serum albumin levels (HR: 0.759, 95% CI: 0.568-1.015, p=0.063) were significant predictors of remission, while serum C3 levels were not. Conclusion: Low serum C3 levels in primary MN are associated with worse baseline clinical and histopathological parameters and higher relapse rates, but are not independently predictive of remission. Serum C3 may be a useful prognostic marker for relapse risk.
  • Article
    Long-Term Prognosis of Acute Myocardial Infarction Caused by Isolated Diffuse Coronary Artery Ectasia
    (Lippincott Williams & Wilkins, 2026-03) Abaci, Adnan; Yerlikaya, Murat Gokhan; Şahin, Tuğba; Savas, Goktug; Akyuz, Ali Riza; Uslu, Sukriye; Çekin, Muhammed Esad ; Hoşoğlu, Ayşe ; Bağci, Ali; Arslan, Abdulsamet; Çiçekcibaşi, Oğuz; Durmaz, Fatih Enes; Sevgican, Cihan İlyas; Ari, Hasan; Kapansahin, Tugba
    BACKGROUND:Isolated coronary artery ectasia (CAE) is a less common form of CAE. The clinical significance of isolated CAE has not been elucidated yet. We aimed to compare the patients with myocardial infarction (MI) due to isolated CAE with the patients without CAE. METHODS:We retrospectively included patients who underwent coronary angiography with a diagnosis of first MI caused by isolated CAE. We excluded patients with >20% stenosis in any vessel other than the lesion responsible for the MI. A second group of patients with MI without CAE was selected as the control group. The primary outcome was the composite of all-cause death and nonfatal recurrent MI occurring after index hospitalization. RESULTS:A total of 404 patients were included. Overall, 63.9% of MIs were ST-elevation MI. Almost all patients in the isolated CAE group had multivessel diffuse ectasia, with 71.3% classified as Markis I, and 26.7% as Markis II. Death or MI recurrence occurred in 54 (26.7%) patients in the isolated CAE group and 33 (16.3%) patients in the control group (P=0.011). Death occurred in 8 (4.0%) patients in the isolated CAE group versus 6 (3.0%) patients in the control group; recurrent MI in 46 (22.8%) versus 27 (13.4%) patients, respectively. Stent thrombosis was more common in the CAE group compared with the control group (8.9% versus 1.5%; P<0.001). In multiple variable analysis, the presence of CAE was associated with death/recurrent MI (hazard ratio, 1.84 [95% CI, 1.11-3.05]; P=0.017), and recurrent MI (hazard ratio, 2.07 [95% CI, 1.08-3.96]; P=0.029). CONCLUSIONS:The patients with MI due to isolated CAE had a higher risk of recurrent MI and stent thrombosis compared with the patients without CAE. In this study, the rate of recurrent MI from the index infarct artery was also higher in the patients with CAE.
  • Article
    Inflammation-Tumor Burden Interaction Score Stratifies Survival after Irinotecan-Eluting Bead Chemoembolization for Colorectal Liver Metastases
    (Frontiers Media SA, 2026-03-12) Doğan, Tolga; Taş, Semra; Hafızoğlu, Emre; Kantar, Taliha Guclu; Demirel, Burcin Cakan; İspir, Emre; Comut, Erdem; Arslan, Muhammet; Taskoylu, Burcu Yapar; Demiray, Atike Gokcen; Yaren, Arzu; Dogu, Gamze Gokoz; Gököz Doğu, Gamze; Çakan Demirel, Burçin; Güçlü Kantar, Taliha
    Background: Transarterial chemoembolization with irinotecan-loaded drug-eluting beads is an established locoregional option for selected patients with colorectal liver metastases who are not candidates for resection or ablation, but survival outcomes remain heterogeneous and simple prognostic tools are lacking. Methods: In this retrospective single-center study, we analyzed 70 patients treated between 2015 and 2024 to investigate whether the interaction between systemic inflammation and liver tumor burden can stratify survival after this procedure. Dynamic inflammatory change was quantified using the difference in the C-reactive protein-to-albumin ratio (Delta CAR) between baseline and early post-treatment assessments, and liver tumor burden was categorized by the number of metastases (< 5 vs. >= 5). These components were integrated into a composite chemoembolization-tumor burden-inflammation balance score (CT-IBS), and its association with early radiologic response, progression-free survival, and overall survival was evaluated using Kaplan-Meier analysis, receiver operating characteristic curves, and multivariable Cox regression. Results: At a median follow-up of 20.3 months, median progression-free and overall survival were 9.1 and 18.9 months, respectively, and early radiologic response (complete or partial) was observed in 75.7% of patients. Higher Delta CAR and a greater number of liver metastases were independently associated with inferior overall survival. The CT-IBS stratified patients into three distinct prognostic groups (median overall survival 27.3 vs. 17.8 vs. 8.6 months; p < 0.001; area under the curve 0.703). Conclusion: Integrating dynamic inflammatory changes with liver tumor burden yields a simple, reproducible classification that may support risk stratification, patient selection, and post-treatment surveillance after irinotecan-eluting bead chemoembolization for colorectal liver metastases.
  • Article
    Genomic Dissection of Pediatric Protein-Losing Enteropathy and Related Disorders: Clinical, Immunologic, and Therapeutic Insights
    (W.B. Saunders, 2026-04) Sefer, Asena Pinar; Erman, Baran; Baris, Safa; Karakoc-Aydiner, Elif; Aydogdu, Emine Selva; Cevahir, Simanur; Can, Salim; Bulutoglu, Alper; Hubrack, Satanay; Whitmore, Katherine; Makhlouf, Melanie; Saraiva, Luis R.; Onder, Gizem; Hatirnaz, Ozden; İslek, Ali; Beser, Omer Faruk; Ertem, Deniz; Kiykim, Ayca; Yilmaz, Ebru Arik; Koca, Tugba Gursoy; Ozen, Ahmet
  • Article
    Follow-Up of Post-Traumatic Headache Patients: A Multicenter Prospective Study on Headache Phenotype and Impact after Mild Traumatic Brain Injury
    (SAGE Publications Inc, 2026-04-07) Atalar, Arife Cimen; Yilmaz, Gulcan Gocmez; Baykan, Betul; Tasdelen, Bahar; Uluduz, Derya; Bolay, Hayrunnisa; Togha, Mansoureh; Salami, Zhale; Arabi, Sepideh; Gölen, Meltem Karacan; Luvsannorov, Otgonbayar; Batmagnai, Khaliunaa; Oguz-Akarsu, Emel; Mesut, Gizem; Durak, Vahide Aslıhan; Ergin, Nesrin; Polat, Burcu; Engin, Berk Enes; Şahbaz, Fatma Gülhan; Örün, Muhammet Okay; Özge, Aynur
    Post-traumatic headache (PTH) is one of the most disabling sequelae of mild traumatic brain injury (mTBI); however, its clinical determinants and long-term trajectories remain poorly defined. We conducted a large, multicenter, prospective follow-up study to characterize the phenotypic spectrum of persistent PTH, identify predictors of persistence, and explore the role of pre-existing migraine in shaping headache outcomes after mTBI. A total of 478 adults (52.1% male, mean age 40.5 +/- 18.7 years) with mTBI were recruited and evaluated by experienced neurologists at two time points: immediately after mTBI and at 6 months post injury. Demographic data and detailed headache features were collected using clinical examination and standardized questionnaires, administered face-to-face during the first visit and either face-to-face or by phone at the 6-month follow-up by physicians. Headache-related disability, depression, and insomnia were assessed using the Headache Impact Test (HIT-6), Beck Depression Inventory (BDI), and Insomnia Severity Index (ISI), respectively. Statistical analyses included classification tree analysis to identify predictors of persistent PTH and K-means clustering to delineate phenotypic subgroups. Overall, 22.6% of patients developed persistent PTH at 6 months. Pre-existing headache (PH) was reported in 31.4% of participants, predominantly migraine (57.3%). Patients with pre-existing migraine more frequently exhibited migraine-like PTH features (throbbing quality, unilateral localization, longer headache attack duration, and associated symptoms such as nausea, photophobia, and phonophobia) and scored significantly higher on the HIT-6, numeric rating scale (NRS) for headache severity, ISI, and BDI, indicating greater disability, pain severity, insomnia, and depressive symptoms (p < 0.01 for all). Classification tree analysis revealed two robust predictors of persistent PTH: acute PTH lasting more than 30 consecutive days and an initial HIT-6 score greater than 45. Furthermore, cluster analysis of patients with persistent PTH identified two phenotypic groups. Cluster 1 (n = 47) comprised patients with >= 180 days of continuous headache, high disability, and poor sleep quality, whereas Cluster 2 (n = 60) included patients with shorter headache duration following mTBI (<180 days), lower disability, and infrequent, shorter headache attacks. This study demonstrates that nearly one in four patients with mTBI experiences persistent PTH. Early indicators of persistence, particularly prolonged continuous headache and higher disability, may help identify high-risk individuals who warrant early aggressive, targeted interventions. Recognition of distinct PTH clusters reflects the heterogeneity of this frequent but under-investigated disorder with high burden and highlights the need for early and tailored management strategies.
  • Article
    Exploring the Prognostic Role of SLC9A1 (NHE1) in Colon Adenocarcinoma: In Silico-Based Bioinformatics-Biophysical Approach
    (Selcuk University, 2026-03-31) Adali, Yasemin; Köseler, Aylin; Özdil, Berrin